Transforming Cardiac Care for Coronary Microvascular Disease

The A-FLUX Reducer System® by VahatiCor tackles the complexities of coronary microvascular dysfunction providing effective relief for patients suffering from chronic symptoms like chest pain and shortness of breath.

A-FLUX Reducer System®
with Swiftcell® Technology

Giving coronary microvascular disease patients a new option for relief

Millions of coronary microvascular disease patients worldwide suffer from persistent pressure, tightness, and chest pain, with no viable options for relief. Living with coronary microvascular disease means constant discomfort and reduced well-being. It’s time for a more effective treatment.

A-FLUX Reducer System®

Minimally-invasive interventional therapy to swiftly relieve coronary microvascular disease symptoms

Rapid

SwiftCell Technology designed to enable more immediate patient response

Reliable

Delivery system intended to provide reliable, straightforward delivery of reducer implant

Relief

Designed to redistribute oxygen supply to achieve RA symptom relief
SwiftCell® Technology

Designed to facilitate swift and targeted therapy

Variable Cell Structure

Optimized to redistribute cardiac blood flow immediately upon delivery

Hourglass Shape

Narrowing designed intended to provide robust performance, regardless of anatomy

Shape-Memory Material

Designed to conform seamlessly to coronary sinus, for proper placement and long-term retention.

VahatiCor’s A-Flux Reducer System™ is an investigational medical device that has not yet been approved by the FDA for commercial distribution in the United States. Any descriptions about the device are based solely on investigational studies and clinical trials, and no such descriptions are intended to be statements regarding the safety or efficacy of the device. VahatiCor has developed a device – the A-Flux Reducer™ – that is currently being tested as an option to relieve pain and discomfort for coronary microvascular disease patients. A-Flux Reducer™, a minimally-invasive and self-expanding device, is designed to restore natural blood flow and ease pressure, heaviness, and tightness of the chest.

M

The incredible team behind vahaticor

Howard Edelman

CEO

Marwan Berrada

FOUNDER AND CHAIRMAN

Kevin Van Bladel

CTO

Michael Mandel

HEAD OF CORPORATE DEVELOPMENT

Mark Niggli

CCO

M

Howard Edelman

CEO

Howard Edelman is a medical device executive accomplished in all aspects of medical product commercialization. Currently, Mr. Edelman is CEO of VahatiCor, a company developing the A-FLUX Reducer System to manage refractory angina. Previously, Mr. Edelman was CEO of Tesa Medical, a provider of the CordaSet orthopedic graft tensioning system, and CEO of Advanced Resin Therapeutics, a provider of a broad-based drug delivery platform. Previously, Mr. Edelman was General Manager of Cothera, a division of United Orthopedic Group (acquired by Breg in 2014).

Howard was the Founder and CEO of VitalWear, a leader in thermal and compression therapy systems. In 2009, VitalWear was named on the INC 500 list of fastest growing private companies and on the San Francisco Business Times Fast 100. He has served in management roles at Johnson & Johnson, Zeiss, CooperVision, and Bio-Rad Laboratories and various startup companies in the Bay Area.

He was Chairman of the Medical Device and Digital Health screening committee of Life Science Angels and was the first Entrepreneur in Residence at the University of San Francisco Innovation Ventures group. Mr. Edelman advises a variety of medical device and biotech companies (iDentical, Karuna Labs, Watershed Medical, Pluto Medical, and Carbon Trainer) and sat on the Research Committee for the Juvenile Diabetes Research Foundation (JDRF). Howard is currently Adjunct Faculty in the Graduate School of Management at the University of San Francisco and holds a B.S. in Biomedical Engineering from Boston University.

M
Marwan Berrada
FOUNDER AND CHAIRMAN
Marwan is an accomplished medical technology leader with a stellar record of leading and developing medical device businesses for over 20 years. In addition to serving as Founder and Chairman of VahatiCor, Marwan currently serves as the President, CEO, and Co-Founder of Advanced NanoTherapies, Inc. and T45 Labs.

An inventor at heart, Marwan works closely with R&D teams and has been a part of several first-generation medical device product launches. He is genuinely passionate about empowering the people around him and driving global medical innovation. Marwan holds a B.S. in Mechanical Engineering from the University of Minnesota and an MBA in Finance from McGill University.

M
Kevin Van Bladel
CTO

Kevin is a distinguished medical technology leader with an impressive career spanning over three decades. Currently, he serves as Chief Technology Officer at VahatiCor Inc., leveraging his strong skills in business analysis, research, project management, and R&D.

Kevin's career includes a 13-year tenure at BioVentrix, where he held the positions of Sr VP of Product & Therapeutic Development and VP of R&D. His expertise in engineering has been demonstrated in various roles at Apsara Medical, BaroSense Inc., Sanarus Medical, Reflow Inc., General Surgical Innovations, Menlo Care (Acquired by J&J), and Mentor Corporation. Kevin holds a B.S. in Physics from Caltech.

M
Michael Mandel
HEAD OF CORPORATE DEVELOPMENT

Michael is an accomplished senior corporate finance and strategic advisory professional with significant experience and a successful track record working with companies in the healthcare industry, with a focus on the medical technology and device sector. Throughout his 25-year investment banking career, Michael has applied his extensive financial expertise to foster growth in both early and late-stage companies. Michael serves as President of SAJ Advisors, Inc. He has previously held roles at Brean Capital, Landmark Ventures, BMO Capital Markets, Banc of America Securities, and Paine Webber. Michael holds a Bachelor of Commerce (Honors) in Finance from the University of Manitoba and an MBA from Columbia Business School.

about the company

A Commitment to Patient-Centric Innovation

At VahatiCor, Inc., a member of the T45 Labs portfolio, we strive to advance the medical technology landscape by creating innovative solutions that address unmet clinical needs and elevate the standard of care. Our goal is to transform patients’ lives worldwide, one breakthrough at a time.

Our approach to frontline interventional treatment for coronary microvascular disease focuses on rapidly providing relief and empowering patients to reclaim their daily lives. We aim to restore vitality and well-being to those affected by this challenging condition by providing an effective and efficient treatment option.

How it works

CONTACT

General Inquiries

info@vahaticor.com

Complaints

complaints@vahaticor.com

Public Affairs

media@vahaticor.com

Headquarters

2903 Bunker Hill Lane, Suite 100, Santa Clara, CA 95054

Phone

+1 (415) 517-0867

References

1. Refractory Angina research report. Delve Insight Business Research, July 2021.

© 2023 VahatiCor, Inc. Products are currently in development and are not available for sale. All rights strictly reserved.
MKT-00001 Rev. A